profit from every SEK 100 of sales.
SEK 0SEK 100
Vitrolife
SEK 119.60-0.42% today
-13.6% in 1 year
1-year low SEK 85.201-year high SEK 139.30
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Vitrolife sold, what it kept, and what it did with the cash.
Sales went from SEK 3.23 billion in 2022 to SEK 3.44 billion in 2025, with -SEK 5.01 billion of profit last year.
SalesProfit
Vitrolife handed back 38% of the cash it generated last year.
SEK 149M
Free cash flow 2025SEK 388M
Bought back its own shares–
Paid as dividendsSEK 149M
Cash vs. debtSEK 809M vs. SEK 1.6B
Vitrolife vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from SEK 100 of sales | Sales growth a year | Price per SEK 1 of profit |
|---|---|---|---|
| Vitrolife | No profit yet | ||
 Abbott Laboratories | 29.3× · Fair price | ||
 Medtronic | 27.4× · Fair price | ||
 Stryker | 38.2× · Expensive | ||
 Edwards Lifesciences | 56.1× · Expensive |
AI analysis
An AI analyst reads Vitrolife's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of SEK | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 3,234 | 3,512 | 3,609 | 3,440 | |
| 1,780 | 1,977 | 2,139 | 1,997 | |
| 647 | 738 | 792 | 574 | |
| 977 | -3,193 | 1,210 | -4,390 | |
| 394 | -3,851 | 513 | -5,012 | |
| 2.91 | -28.44 | 3.79 | -37.01 | |
| 55.0% | 56.3% | 59.3% | 58.1% | |
| 20.0% | 21.0% | 21.9% | 16.7% | |
| 12.2% | -109.7% | 14.2% | -145.7% |
Balance sheet
| In millions of SEK | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 20,551 | 16,329 | 17,446 | 11,124 |
| Cash | 578 | 861 | 1,135 | 809 |
| Total debt | 2,225 | 2,089 | 2,089 | 1,605 |
| Total liabilities | 3,811 | 3,606 | 3,805 | 3,229 |
| 16,736 | 12,722 | 13,639 | 7,894 | |
| 135 | 135 | 136 | 135 | |
| 2.4% | -19.4% | 3.9% | -40.3% | |
| 2.4% | -30.3% | 3.8% | -63.5% |
Cash flow
| In millions of SEK | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 636 | 757 | 907 | 635 | |
| 87 | 119 | 202 | 247 | |
| 549 | 638 | 705 | 388 | |
| Dividends paid | 110 | 115 | 135 | 149 |
| 0 | – | – | – | |
| 10 | 17 | 14 | 15 |
Valuation
- –
- –
- –
- 1.7×
- 4.6×
- 40.9×
- –
- 2.4%
- -31.6%
- 0.9%
Profitability
- 58.1%
- 16.7%
- -145.7%
- –
- -40.3%
- -13.3%
- –
- –
- –
- –
Growth
- +2.1%
- –
- –
- –
- +0.0%
Financial health
- –
- 0.20
- –
- -69.8×
- 3.40
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 12%of 948
Top 30%of 871
Bottom 20%of 868
Top 38%of 985
0.9%of the share price, paid each year
On $1,000 invested$9a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
: 38.4%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
25No pass
Benjamin Graham
57No pass
Philip Fisher
35No pass
Peter Lynch
30No pass
Joel Greenblatt
0No pass
Charlie Munger
36No pass
Terry Smith
28No pass
Questions about Vitrolife
Is Vitrolife a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Vitrolife AI analysis
What does Vitrolife do?
Vitrolife AB (publ) provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas. It is in Medical Devices, based in Gothenburg, Sweden, with 1,126 employees.
Does Vitrolife pay a dividend?
Yes. At today's price the dividend is 0.9% a year. In 2025 it paid out SEK 149 million in dividends.
Is Vitrolife stock halal?
Yes. Vitrolife passes our halal screen: its business is permitted and its debt is 10% of its market value, under the 30% limit. How we check
How has Vitrolife stock done over the past year?
Down 13.6% over the past twelve months, to SEK 119.60. It traded between SEK 85.20 and SEK 139.30 and is 14.1% below its high.
Who are Vitrolife's competitors?
The largest listed companies in the same industry are Abbott Laboratories, Medtronic, Stryker and Edwards Lifesciences. The peers table on this page compares their profit, growth and price with Vitrolife's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.